A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 400 participants.

Also called NCT07220538

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07220538
  • ChiCTR ChiCTR2500107051
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07220538. Randomized; no masking; primary purpose treatment. Start 2025-11-28 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Acronym
GiCIIS
Condition
Ischemic Stroke Hospitalized
Condition
Impairment, Cognitive
Intervention (Drug)
Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.)
Intervention (Other)
Standard of care (SoC) Group
Lead sponsor
Dr. Willmar Schwabe GmbH & Co. KG (class: industry)
Collaborator
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct07220538
Content hash
84372440740eb69270e29b230765606b9f774d31021e796dc8620796c6baf497